How GLP‑1 diabetes and weight‑loss drugs affect pancreas signals and pancreatic cancer risk
Targeting pancreatic endocrine-exocrine signaling in cancer development with incretin mimetics
This project aims to explain how commonly used GLP‑1 diabetes and weight‑loss drugs change communication between hormone-producing and digestive cells in the pancreas and whether that could affect pancreatic cancer risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11262822 on NIH RePORTER |
What this research studies
As a patient, you should know researchers are using advanced lab models that better mimic human pancreas biology to see how GLP‑1 receptor agonists (the incretin mimetics) change signaling between insulin-producing beta cells and digestive acinar cells. The team will combine genetically informed animal and cell-based experiments and molecular analyses to follow how those signaling changes influence early steps in pancreatic tumor formation. The work is motivated by mixed signals from clinical reports and real-world safety databases about whether these drugs change pancreatic cancer risk. Findings are intended to clarify mechanisms so doctors can make safer treatment decisions in the future.
Who could benefit from this research
Good fit: People with obesity or type 2 diabetes who are taking or considering GLP‑1 receptor agonists would be the most relevant group for this research.
Not a fit: People who are not exposed to GLP‑1 drugs or whose cancers are unrelated to pancreatic endocrine–exocrine interactions are unlikely to see direct benefits from this specific project.
Why it matters
Potential benefit: If successful, this work could clarify whether GLP‑1 drugs raise or lower pancreatic cancer risk and guide safer prescribing for people with obesity or diabetes.
How similar studies have performed: Previous clinical reports and preclinical studies have produced mixed and sometimes conflicting results, so this project builds on suggestive but unproven findings.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Muzumdar, Mandar Deepak — Yale University
- Study coordinator: Muzumdar, Mandar Deepak
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.